词条 | Furosemide |
释义 |
| Watchedfields = changed | verifiedrevid = 461114978 | drug_name = | IUPAC_name = 4-Chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid | pronounce = {{IPAc-en|f|j|ʊ|ˈ|ɹ|oʊ|s|ə|ˌ|m|aɪ|d}} | image = Furosemide.svg | image2 = Furosemide-1Z9Y-3D-balls.png | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 7LXU5N7ZO5 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D00331 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 35 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = ZZUFCTLCJUWOSV-UHFFFAOYSA-N | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 54-31-9 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 3322 | ATC_prefix = C03 | ATC_suffix = CA01 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 47426 | PubChem = 3440 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00695 | smiles = o1cccc1CNc(cc2Cl)c(C(=O)O)cc2S(=O)(=O)N | C=12 | H=11 | Cl=1 | N=2 | O=5 | S=1 | molecular_weight = 330.745 g/mol | Drugs.com = {{drugs.com|monograph|furosemide}} | bioavailability = 43–69% | protein_bound = | metabolism = liver and kidney glucuronidation | elimination_half-life = up to 100 minutes | onset = 30 to 60 min (PO), 5 min (IV)[1] | excretion = renal 66%, biliary 33% | pregnancy_AU = C | pregnancy_US = C | DailyMedID = 3940 | legal_status = Rx-only | routes_of_administration = by mouth, IV, IM | synonyms = Frusemide }}Furosemide, sold under the brand name Lasix among others, is a medication used to treat fluid build-up due to heart failure, liver scarring, or kidney disease.[1] It may also be used for the treatment of high blood pressure.[1] It can be taken by injection into a vein or by mouth.[1] When taken by mouth, it typically begins working within an hour, while intravenously, it typically begins working within five minutes.[1] Common side effects include feeling lightheaded with standing, ringing in the ears, and sensitivity to light.[1] Potentially serious side effects include electrolyte abnormalities, low blood pressure, and hearing loss.[1] Blood tests are recommended regularly for those on treatment.[1] Furosemide is a type of loop diuretic that works by decreasing the reabsorption of sodium by the kidneys.[1] Furosemide was patented in 1959 and approved for medical use in 1964.[2] It is on the World Health Organization's List of Essential Medicines, which lists the most effective and safe medicines needed in a health system.[3] The wholesale price in the developing world is between US$0.004 and US$0.02 per day.[4] In the United States, it is available as a generic medication and costs about US$0.15 per day.[1] In 2016, it was the 15th most prescribed medication in the United States, with more than 32 million prescriptions.[5] It is on the World Anti-Doping Agency's banned drug list due to concerns that it may mask other drugs.[6] It has also been used in race horses for the treatment and prevention of exercise-induced pulmonary hemorrhage.[7][8] Medical usesFurosemide is primarily used for the treatment of edema, but also in some cases of hypertension (where there is also kidney or heart impairment).[9] It is the first-line agent in most people with edema caused by congestive heart failure.[9] It is also used for liver cirrhosis, kidney impairment, nephrotic syndrome, in adjunct therapy for swelling of the brain or lungs where rapid diuresis is required (IV injection), and in the management of severe hypercalcemia in combination with adequate rehydration.[10] Kidney diseaseIn chronic kidney diseases with hypoalbuminemia, it is used along with albumin to increase diuresis. It is also used along with albumin in nephrotic syndrome to reduce edema. [11]Other information
Adverse effectsFurosemide also can lead to gout caused by hyperuricemia. Hyperglycemia is also a common side effect. The tendency, as for all loop diuretics, to cause low serum potassium concentration (hypokalemia) has given rise to combination products, either with potassium or with the potassium-sparing diuretic amiloride (Co-amilofruse). Other electrolyte abnormalities that can result from furosemide use include hyponatremia, hypochloremia, hypomagnesemia, and hypocalcemia.[14] In the treatment of heart failure, many studies have shown that the long-term use of furosemide can cause varying degrees of thiamine deficiency, so thiamine supplementation is also suggested.[15] Although disputed,[16] it is considered ototoxic: "usually with large intravenous doses and rapid administration and in renal impairment".[17] Other precautions include: nephrotoxicity, sulfonamide (sulfa) allergy, and increases free thyroid hormone effects with large doses.[18] InteractionsFurosemide has potential interactions with these medications:[19]
Potentially hazardous interactions with other drugs:
Mechanism of action{{Main|Loop diuretic}}Furosemide, like other loop diuretics, acts by inhibiting the luminal Na-K-Cl cotransporter in the thick ascending limb of the loop of Henle, by binding to the chloride transport channel, thus causing sodium, chloride, and potassium loss in urine.[20] The action on the distal tubules is independent of any inhibitory effect on carbonic anhydrase or aldosterone; it also abolishes the corticomedullary osmotic gradient and blocks negative, as well as positive, free water clearance. Because of the large NaCl absorptive capacity of the loop of Henle, diuresis is not limited by development of acidosis, as it is with the carbonic anhydrase inhibitors. Additionally, furosemide is a noncompetitive subtype-specific blocker of GABA-A receptors.[21][22][23] Furosemide has been reported to reversibly antagonize GABA-evoked currents of α6β2γ2 receptors at µM concentrations, but not α1β2γ2 receptors.[21][23] During development, the α6β2γ2 receptor increases in expression in cerebellar granule neurons, corresponding to increased sensitivity to furosemide.[22] Pharmacokinetics
The pharmacokinetics of furosemide are apparently not significantly altered by food.[33] No direct relationship has been found between furosemide concentration in the plasma and furosemide efficacy. Efficacy depends upon the concentration of furosemide in urine.[13] NamesFurosemide is the INN and BAN.[34] The previous BAN was frusemide. Some of the brand names under which furosemide is marketed include: Aisemide, Apo-Furosemide, Beronald, Desdemin, Discoid, Diural, Diurapid, Dryptal, Durafurid, Edemid, Errolon, Eutensin, Flusapex, Frudix, Frusetic, Frusid, Fulsix, Fuluvamide, Furesis, Furix, Furo-Puren, Furon, Furosedon, Fusid.frusone, Hydro-rapid, Impugan, Katlex, Lasilix, Lasix, Lodix, Lowpston, Macasirool, Mirfat, Nicorol, Odemase, Oedemex, Profemin, Rosemide, Rusyde, Salix, Seguril, Teva-Furosemide, Trofurit, Uremide, and Urex. Veterinary usesThe diuretic effects are put to use most commonly in horses to prevent bleeding during a race. Sometime in the early 1970s, furosemide's ability to prevent, or at least greatly reduce, the incidence of bleeding (exercise-induced pulmonary hemorrhage) by horses during races was discovered accidentally. In the United States of America, pursuant to the racing rules of most states, horses that bleed from the nostrils three times are permanently barred from racing. Clinical trials followed, and by decade's end, racing commissions in some states in the USA began legalizing its use on race horses. On September 1, 1995, New York became the last state in the United States to approve such use, after years of refusing to consider doing so. Some states allow its use for all racehorses; some allow it only for confirmed "bleeders". Its use for this purpose is still prohibited in many other countries. Furosemide is also used in horses for pulmonary edema, congestive heart failure (in combination with other drugs), and allergic reactions. Although it increases circulation to the kidneys, it does not help kidney function, and is not recommended for kidney disease. It is also used to treat congestive heart failure (pulmonary edema, pleural effusion, and/or ascites) in cats and dogs.[35] It can also be used in an attempt to promote urine production in anuric or oliguric acute renal failure. HorsesFurosemide is injected either intramuscularly or intravenously, usually 0.5-1.0 mg/kg twice/day, although less before a horse is raced. As with many diuretics, it can cause dehydration and electrolyte imbalance, including loss of potassium, calcium, sodium, and magnesium. Excessive use of furosemide will most likely lead to a metabolic alkalosis due to hypochloremia and hypokalemia. The drug should, therefore, not be used in horses that are dehydrated or experiencing kidney failure. It should be used with caution in horses with liver problems or electrolyte abnormalities. Overdose may lead to dehydration, change in drinking patterns and urination, seizures, gastrointestinal problems, kidney damage, lethargy, collapse, and coma. Furosemide should be used with caution when combined with corticosteroids (as this increases the risk of electrolyte imbalance), aminoglycoside antibiotics (increases risk of kidney or ear damage), and trimethoprim sulfa (causes decreased platelet count). It may also cause interactions with anesthetics, so its use should be related to the veterinarian if the animal is going into surgery, and it decreases the kidneys' ability to excrete aspirin, so dosages will need to be adjusted if combined with that drug. Furosemide may increase the risk of digoxin toxicity due to hypokalemia. The drug is best not used during pregnancy or in a lactating mare, as it has been shown to be passed through the placenta and milk in studies with other species. It should not be used in horses with pituitary pars intermedia dysfunction (Cushings). Furosemide is detectable in urine 36–72 hours following injection. Its use is prohibited by most equestrian organizations. References1. ^1 2 3 4 5 6 7 8 9 10 {{cite web|title=Furosemide|url=https://www.drugs.com/monograph/furosemide.html|publisher=The American Society of Health-System Pharmacists|accessdate=October 23, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151119161939/http://www.drugs.com/monograph/furosemide.html|archivedate=2015-11-19|df=}} 2. ^{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=458 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA458 |language=en}} 3. ^{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}} 4. ^{{cite web|title=Furosemide|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=363&searchYear=2014|website=International Drug Price Indicator Guide|accessdate=24 October 2015|deadurl=no|archiveurl=https://web.archive.org/web/20170510104950/http://mshpriceguide.org/en/single-drug-information/?DMFId=363&searchYear=2014|archivedate=10 May 2017|df=}} 5. ^{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}} 6. ^{{cite web|title=THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD|url=https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-prohibited-list-2014-EN.pdf|accessdate=24 October 2015|page=5|format=pdf|date=2014|deadurl=no|archiveurl=https://web.archive.org/web/20160115033743/https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-prohibited-list-2014-EN.pdf|archivedate=15 January 2016|df=}} 7. ^{{cite journal|last1=Sullivan|first1=S|last2=Hinchcliff|first2=K|title=Update on exercise-induced pulmonary hemorrhage.|journal=The Veterinary Clinics of North America. Equine Practice|date=April 2015|volume=31|issue=1|pages=187–98|pmid=25770069|doi=10.1016/j.cveq.2014.11.011}} 8. ^{{cite journal|last1=Hinchcliff|first1=KW|last2=Couetil|first2=LL|last3=Knight|first3=PK|last4=Morley|first4=PS|last5=Robinson|first5=NE|last6=Sweeney|first6=CR|last7=van Erck|first7=E|title=Exercise induced pulmonary hemorrhage in horses: American College of Veterinary Internal Medicine consensus statement.|journal=Journal of Veterinary Internal Medicine / American College of Veterinary Internal Medicine|date=2015|volume=29|issue=3|pages=743–58|pmid=25996660|doi=10.1111/jvim.12593|pmc=4895427}} 9. ^1 {{cite web|title=Furosemide|url=https://www.drugs.com/monograph/furosemide.html|work=The American Society of Health-System Pharmacists|accessdate=3 April 2011|deadurl=no|archiveurl=https://web.archive.org/web/20110317080203/http://www.drugs.com/monograph/furosemide.html|archivedate=17 March 2011|df=}} 10. ^{{cite book |editor=Rossi S |title=Australian Medicines Handbook 2004 |edition=5th |isbn=978-0-9578521-4-3 |url=http://www.amh.net.au/ |year=2004 |publisher=Australian Medicines Handbook Pty Ltd |location=Adelaide, S.A. }} 11. ^BMC Nephrol. 2012 Aug 29;13:92. doi: 10.1186/1471-2369-13-92.The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study.Phakdeekitcharoen B1, Boonyawat K Ann Pharmacother. 2003 May;37(5):695-700.Combined furosemide and human albumin treatment for diuretic-resistant edema.Elwell RJ1, Spencer AP, Eisele G 12. ^{{cite web |title=British National Formulary |url=https://bnf.nice.org.uk/drug/furosemide.html#renalImpairment |accessdate=9 November 2018}} 13. ^1 2 {{cite journal |last1=Ponto |first1=LL |last2=Schoenwald |first2=RD |title=Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). |journal=Clinical Pharmacokinetics |date=May 1990 |volume=18 |issue=5 |pages=381–408 |doi=10.2165/00003088-199018050-00004 |pmid=2185908 }} 14. ^{{cite journal |last1=Oh |first1=SW |last2=Han |first2=SY |title=Loop Diuretics in Clinical Practice. |journal=Electrolyte & Blood Pressure|date=June 2015 |volume=13 |issue=1 |pages=17–21 |doi=10.5049/EBP.2015.13.1.17 |pmid=26240596|pmc=4520883 }} 15. ^{{cite journal|last1=Katta|first1=N|last2=Balla|first2=S|last3=Alpert|first3=MA|title=Does Long-Term Furosemide Therapy Cause Thiamine Deficiency in Patients with Heart Failure? A Focused Review.|journal=The American Journal of Medicine|date=July 2016|volume=129|issue=7|pages=753.e7–753.e11|doi=10.1016/j.amjmed.2016.01.037|pmid=26899752}} 16. ^{{cite journal | vauthors = Rais-Bahrami K, Majd M, Veszelovszky E, Short B | title = Use of furosemide and hearing loss in neonatal intensive care survivors | journal = Am J Perinatol | volume = 21 | issue = 6 | pages = 329–32 | year = 2004 | pmid = 15311369 | doi = 10.1055/s-2004-831887}} 17. ^BNF 45 March 2003 18. ^{{Cite web|url=https://www.uptodate.com/contents/furosemide-drug-information?search=furosemide&source=search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1#F174802|title=UpToDate|website=www.uptodate.com|access-date=2018-11-06}} 19. ^Brand name:Lasix - Generic name: Furosemide Prescription Drug Information, Side Effects - PDRHealth 20. ^{{cite book|last1=Dowd|first1=Frank J|last2=Johnson|first2=Bart|last3=Mariotti|first3=Angelo|title=Pharmacology and Therapeutics for Dentistry - E-Book|date=3 September 2016|publisher=Elsevier Health Sciences|isbn=9780323445955|pages=324–326|url=https://books.google.com.my/books?id=6xT7DAAAQBAJ&pg=PA326|accessdate=4 November 2017}} 21. ^1 {{cite journal |vauthors=Korpi ER, Kuner T, Seeburg PH, Lüddens H |title=Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor |journal=Mol. Pharmacology. |volume=47 |issue=2 |pages=283–9 |year=1995 |pmid=7870036 |doi=}} 22. ^1 {{cite journal |vauthors=Tia S, Wang JF, Kotchabhakdi N, Vicini S |title=Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit |journal=J. Neurosci. |volume=16 |issue=11 |pages=3630–40 |year=1996 |pmid=8642407 |doi= |url=http://www.jneurosci.org/cgi/content/full/16/11/3630 |deadurl=no |archiveurl=https://web.archive.org/web/20070927203857/http://www.jneurosci.org/cgi/content/full/16/11/3630 |archivedate=2007-09-27 |df= }} 23. ^1 {{cite journal |vauthors=Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ |title=Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit |journal=Mol. Pharmacol. |volume=50 |issue=3 |pages=670–8 |year=1996 |pmid=8794909 |doi=}} 24. ^AMA Department of Drugs: Drug Evaluations Subscription, American Medical Association, Chicago, IL, 1990. 25. ^Knoben JE & Anderson PO (Eds): Handbook of Clinical Drug Data, 6th. Drug Intelligence Publications, Inc, Hamilton, IL, 1988. 26. ^1 2 3 Product Information: Lasix(R), furosemide. Aventis Pharmaceuticals, Bridgewater, NJ, 2004. 27. ^1 2 3 4 Gilman AG, Rall TW, Nies AS, et al (Eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th. Pergamon Press, New York, NY, 1990. 28. ^1 2 3 4 {{Cite journal|last=Kelly|first=M. R.|last2=Cutler|first2=R. E.|last3=Forrey|first3=A. W.|last4=Kimpel|first4=B. M.|date=February 1974|title=Pharmacokinetics of orally administered furosemide|journal=Clinical Pharmacology and Therapeutics|volume=15|issue=2|pages=178–186|issn=0009-9236|pmid=4812154}} 29. ^{{Cite journal|last=Verbeeck|first=R. K.|last2=Patwardhan|first2=R. V.|last3=Villeneuve|first3=J. P.|last4=Wilkinson|first4=G. R.|last5=Branch|first5=R. A.|date=June 1982|title=Furosemide disposition in cirrhosis|journal=Clinical Pharmacology and Therapeutics|volume=31|issue=6|pages=719–725|issn=0009-9236|pmid=7075120}} 30. ^{{Cite journal|last=Chaturvedi|first=P. R.|last2=O'Donnell|first2=J. P.|last3=Nicholas|first3=J. M.|last4=Shoenthal|first4=D. R.|last5=Waters|first5=D. H.|last6=Gwilt|first6=P. R.|date=March 1987|title=Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure|journal=International Journal of Clinical Pharmacology, Therapy, and Toxicology|volume=25|issue=3|pages=123–128|issn=0174-4879|pmid=3557737}} 31. ^{{Cite journal|last=Brater|first=D.C.|date=1991|title=Clinical Pharmacology of Loop Diuretics|journal=Drugs|language=en|volume=41|issue=Supplement 3|pages=14–22|doi=10.2165/00003495-199100413-00004|pmid=1712712|issn=0012-6667}} 32. ^{{Cite journal|last=Haegeli|first=Laurent|last2=Brunner-La Rocca|first2=Hans Peter|last3=Wenk|first3=Markus|last4=Pfisterer|first4=Matthias|last5=Drewe|first5=Jürgen|last6=Krähenbühl|first6=Stephan|date=December 2007|title=Sublingual administration of furosemide: new application of an old drug|journal=British Journal of Clinical Pharmacology|volume=64|issue=6|pages=804–809|doi=10.1111/j.1365-2125.2007.03035.x|issn=1365-2125|pmc=2198789|pmid=17875188}} 33. ^AHFS Drug Information 2004. McEvoy GK, ed. Furosemide. American Society of Health-System Pharmacists; 2004: 2260-4. 34. ^{{cite web |url=http://www.mhra.gov.uk/Howweregulate/Medicines/Namingofmedicines/ChangestomedicinesnamesBANstorINNs/index.htm |title=Naming human medicines |accessdate=2009-11-18 |deadurl=no |archiveurl=https://web.archive.org/web/20100427025454/http://www.mhra.gov.uk/Howweregulate/Medicines/Namingofmedicines/ChangestomedicinesnamesBANstorINNs/index.htm |archivedate=2010-04-27 |df= }} 35. ^{{cite book |last1=Kittleson |first1=Mark |authorlink1=Mark Kittleson |last2=Kienle |first2=Richard |date=1998 |title=Small Animal Cardiovascular Medicine |isbn=978-0-8151-5140-1}} Further reading
External links
| title = Pharmacodynamics | titlestyle = background:#ccccff | list1 ={{GABA receptor modulators}}{{Glutamate metabolism and transport modulators}}{{Glycine receptor modulators}}{{Ionotropic glutamate receptor modulators}}{{Symporter inhibitors}} }}{{portal bar|Pharmacy and pharmacology|Medicine}} 16 : Anthranilic acids|Carbonic anhydrase inhibitors|Chemical substances for emergency medicine|Equine medications|Furans|GABAA receptor negative allosteric modulators|Glycine receptor antagonists|Loop diuretics|NMDA receptor antagonists|Chloroarenes|Sulfonamides|World Health Organization essential medicines|RTT|World Anti-Doping Agency prohibited substances|Nephrotoxins|Sanofi |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。